NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity

被引：33

作者：

Amin, Saiful ^{[1
]}

Aktar, Salma ^{[2
]}

Rahman, Md Mijanur ^{[2
]}

Chowdhury, Mohammed Mehadi Hassan ^{[2
]}

机构：

[1] Chittagong Med Univ, Chattogram, Bangladesh

[2] Noakhali Sci & Technol Univ, Dept Microbiol, Sonapur 3814, Noakhali, Bangladesh

来源：

MICROBES AND INFECTION | 2022年 / 24卷 / 01期

关键词：

NLRP3; inflammasome; Immune response; COVID-19; Risk factors; Therapeutics; MITOCHONDRIAL-DNA; IMMUNE-RESPONSES; INFECTION; SYSTEM; PATHOGENESIS; MONOCYTES; CASPASE-1; PNEUMONIA; RECEPTOR; INJURY;

D O I：

10.1016/j.micinf.2021.104913

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

NLRP3 inflammasome is a critical immune component that plays a crucial role in mounting innate immune responses. The deleterious effects of inflammasome activation have been correlated with the COVID-19 disease severity. In the presence of several underlying disorders, the immune components of our bodies are dysregulated, creating conditions that could adversely affect us other than providing a required level of protection. In this review, we focused on the occurrence of NLRP3 inflammasome activation in response to SARS-COV-2 infection, dysregulation of NLRP3 activation events in the presence of several comorbidities, the contribution of activated NLRP3 inflammasome to the severity of COVID-19, and available therapeutics for the treatment of such NLRP3 inflammasome related diseases based on current knowledge. The primed state of immunity in individuals with comorbidities (risk factors) could accelerate many deaths and severe COVID-19 cases via activation of NLRP3 inflammasome and the release of downstream inflammatory molecules. Therefore, a detailed understanding of the host-pathogen interaction is needed to clarify the pathophysiology and select a potential therapeutic approach.(c) 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

引用

页数：10

共 111 条

[1] Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease [J].